
Trastuzumab Deruxtecan Yields Promising Intracranial Activity in Patients With HER2+/HER2-Low Breast Cancer and Brain ...
A retrospective multicenter real-world study shows that trastuzumab deruxtecan (T-DXd; Darzalex; Johnson & Johnson) shows promising intracranial activity in patients with HER2-positive (HER2+)/HER2-low metastatic breast cancer (mBC) with active …